Podcasts

TKI Discontinuation in Patients With CML

04/07/2020

Ehab Atallah, MD, Professor of Medicine, Medical College of Wisconsin, Milwaukee, discusses the do’s and don’ts of tyrosine kinase inhibitor (TKI) treatment discontinuation in patients with chronic myeloid leukemia (CML).

Recent News

News

Berzosertib Plus Topotecan for Patients With Relapsed Platinum-Resistant Small-Cell Lung Cancer: DDRiver SCLC 250 Study

01/15/2026

Gina Tomaine

Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.

Berzosertib plus topotecan did...

01/15/2026

Oncology

News

Prophylactic Tocilizumab May Limit Tarlatamab Toxicities for High-Risk Patients With Extensive-Stage Small Cell and Neuroendocrine Lung Cancer

01/15/2026

Gina Tomaine

Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...

Tarlatamab for patients with...

01/15/2026

Oncology

News

Oral Iberdomide Combination Demonstrates Clinically Meaningful Activity for R/R Multiple Myeloma

01/14/2026

Emily Estrada

The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.

The all-oral combination of...

01/14/2026

Oncology

News

High Non-Relapse Mortality Remains Barrier to Allogeneic Transplantation Success Rates for Patients With Myelofibrosis

01/14/2026

Emily Estrada

Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.

Among patients with...

01/14/2026

Oncology

News

Pacritinib Therapy Shows Improved Symptom Reduction and Spleen Response for Patients With Myelofibrosis and Thrombocytopenia

01/14/2026

Emily Estrada

Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...

Pacritinib therapy showed...

01/14/2026

Oncology

News

Pegylated Liposomal Doxorubicin Significantly Extends Progression-Free Survival in Advanced Desmoid Tumors

01/13/2026

Stephanie Holland

Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors.

Results from a phase 3 trial...

01/13/2026

Oncology

News

Andamertinib Demonstrates Clinical Promise for Pretreated Patients With EGFR-Mutated NSCLC

01/13/2026

Stephanie Holland

Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...

Results from the phase 2 KANNON...

01/13/2026

Oncology

Conference Coverage

Lirafugratinib Demonstrates Efficacy, Safety for Previously Treated Patients With FGFR2 Fusion-Positive Cholangiocarcinoma

01/13/2026

Stephanie Holland

Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.

Results from the phase 1/2...

01/13/2026

Oncology

News

Eflornithine Plus Lomustine vs Lomustine Monotherapy for Recurrent Grade 3 Astrocytoma: Phase 3 STELLAR Trial

01/13/2026

Gina Tomaine

Results showed that eflornithine combined with lomustine significantly prolonged both progression-free and overall survival for patients with recurrent IDH-mutant, grade 3 astrocytoma, compared with lomustine monotherapy.

Results showed that eflornithine...

01/13/2026

Oncology

Conference Coverage

Addition of Tislelizumab to Neoadjuvant Chemoradiotherapy Shows Clinical Promise for Gastric/GEJ Cancer

01/13/2026

Stephanie Holland

Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.

Phase 2b results from the...

01/13/2026

Oncology